Trial
NCT04087590
Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Hospital, Lille
Collaborators
AstraZeneca
Condition
Copd
Intervention
Formoterol-glycopyrronium co suspension (PT003)
Why stopped
Following Brexit and the unavailability of the experimental drug (PT003) in France, the study was terminated prematurely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20